We found that downregulation of FGF19 inhibited the progression of tumor cells, whereas administration of AZD2014 did not further increase this inhibitory effect, both in tumor volume and Ki-67, p-AKT expression levels (Supplementary Fig. 6). The gene discussed is AKT1; the disease is neoplasm.